Somnath Banerjee Vs Apex Lab (Competition Commission of India)
The Competition Commission of India (CCI) recently addressed a complaint filed by Mr. Somnath Banerjee against various entities in the pharmaceutical industry, alleging violations of competition laws. The complaint centered around the marketing and promotion practices of his patented dietary supplement, ‘Protestin,’ sold by Reserca Health Care Pvt. Ltd. This article delves into the details of the case, the arguments presented, and the CCI’s ruling.
Mr. Somnath Banerjee, the informant, alleged that his product, Protestin, was not adequately marketed and promoted due to non-cooperation from private hospitals, pharmaceutical companies, e-pharmacies, and other entities. He cited reasons such as lack of permission from regulatory authorities and competition from other brands for the subdued promotion of his product. The informant sought reliefs including compensation for damages and permission for digital marketing and virtual communication.
Upon examination, the CCI found no evidence of anti-competitive conduct or agreements among the accused parties. The emails presented by the informant were deemed as solicitation attempts rather than indicative of collusion. The CCI emphasized that commercial decisions in the market are primarily driven by commercial considerations, and intervention is unwarranted in the absence of anti-competitive behavior.
The Commission concluded that no contravention of competition laws was evident, specifically Section 3(4) read with Section 3(1) of the Competition Act, 2002. Consequently, the matter was closed under Section 26(2) of the Act, and no relief was granted as per Section 33.
